Published in J Biol Chem on January 31, 2001
Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov (2009) 3.66
Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med (2005) 3.41
Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev (2006) 3.30
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol (2006) 1.99
IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 1.95
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 1.88
Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature (2008) 1.88
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov (2012) 1.62
NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry (2012) 1.60
Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics (2010) 1.59
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells (2011) 1.48
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol (2011) 1.30
Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI. Nat Struct Mol Biol (2011) 1.29
Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol (2011) 1.23
Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem (2009) 1.22
Production of therapeutic antibodies with controlled fucosylation. MAbs (2009) 1.17
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther (2009) 1.17
Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. Biochemistry (2008) 1.17
Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem (2011) 1.12
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol (2012) 1.11
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica (2012) 1.09
Structural determinants of unique properties of human IgG4-Fc. J Mol Biol (2013) 1.09
Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A (2009) 1.04
Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc Natl Acad Sci U S A (2011) 1.04
Function and 3D structure of the N-glycans on glycoproteins. Int J Mol Sci (2012) 1.04
Structure of an isolated unglycosylated antibody C(H)2 domain. Acta Crystallogr D Biol Crystallogr (2008) 1.03
Synthetic cell surface receptors for delivery of therapeutics and probes. Adv Drug Deliv Rev (2012) 1.01
Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. PLoS Pathog (2014) 1.00
A conformation-induced oligomerization model for B cell receptor microclustering and signaling. Curr Top Microbiol Immunol (2010) 0.99
Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics (2011) 0.99
Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity. Immunology (2003) 0.98
It's all about change: the antigen-driven initiation of B-cell receptor signaling. Cold Spring Harb Perspect Biol (2010) 0.97
Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc (2013) 0.96
Porcine IgG: structure, genetics, and evolution. Immunogenetics (2008) 0.96
A fluorescent biosensor reveals conformational changes in human immunoglobulin E Fc: implications for mechanisms of receptor binding, inhibition, and allergen recognition. J Biol Chem (2012) 0.96
The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology (2008) 0.95
Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci U S A (2015) 0.94
Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One (2013) 0.94
Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nat Commun (2015) 0.93
Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors. MAbs (2009) 0.93
Pentraxins and Fc receptors. Immunol Rev (2012) 0.92
A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun (2009) 0.91
An unusual Fc receptor-related protein expressed in human centroblasts. Proc Natl Acad Sci U S A (2002) 0.90
The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol (2008) 0.90
Bi-specific aptamers mediating tumor cell lysis. J Biol Chem (2011) 0.87
scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cancer Res (2013) 0.87
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant. MAbs (2013) 0.86
Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP). Clin Exp Immunol (2010) 0.86
Human IgG4: a structural perspective. Immunol Rev (2015) 0.85
The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity. J Biol Chem (2014) 0.84
Principles of antibody-mediated TNF receptor activation. Cell Death Differ (2015) 0.84
CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol (2014) 0.84
Crystal structure of deglycosylated human IgG4-Fc. Mol Immunol (2014) 0.83
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res (2014) 0.83
Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments. J Biol Chem (2012) 0.82
Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding. Acta Crystallogr D Biol Crystallogr (2015) 0.82
TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev (2015) 0.81
The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor. J Mol Biol (2008) 0.81
Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets (2014) 0.81
Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. MAbs (2014) 0.81
Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gammaRI. FASEB J (2008) 0.81
The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands. J Biol Chem (2015) 0.81
A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry (2015) 0.80
IgG4 Characteristics and Functions in Cancer Immunity. Curr Allergy Asthma Rep (2016) 0.79
Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity. MAbs (2015) 0.79
Increased survival and reduced renal injury in MRL/lpr mice treated with a human Fcγ receptor II (CD32) peptide. Immunology (2012) 0.78
Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Semin Immunopathol (2014) 0.77
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. J Immunol (2015) 0.76
Hydrophobic interactions are the driving force for the binding of peptide mimotopes and Staphylococcal protein A to recombinant human IgG1. Eur Biophys J (2007) 0.76
Effects of anchor structure and glycosylation of Fcγ receptor III on ligand binding affinity. Mol Biol Cell (2016) 0.76
CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies. Bioengineered (2012) 0.75
Immunomodulatory effects of Newcastle disease virus AF2240 strain on human peripheral blood mononuclear cells. Int J Med Sci (2014) 0.75
Fc gamma receptors: glycobiology and therapeutic prospects. J Inflamm Res (2016) 0.75
Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein. Mol Pharm (2013) 0.75
Pentraxins and IgA share a binding hot-spot on FcαRI. Protein Sci (2014) 0.75
Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life. Front Immunol (2016) 0.75
Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa. J Struct Biol (2016) 0.75
The Role and Function of Fcγ Receptors on Myeloid Cells. Microbiol Spectr (2016) 0.75
Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab. Mol Cell Proteomics (2017) 0.75
Characterization of conformational deformation-coupled interaction between immunoglobulin G1 Fc glycoprotein and a low-affinity Fcγ receptor by deuteration-assisted small-angle neutron scattering. Biochem Biophys Rep (2017) 0.75
Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature (2000) 3.54
Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature (1969) 2.75
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 2.41
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
Crystal structure of formate dehydrogenase H: catalysis involving Mo, molybdopterin, selenocysteine, and an Fe4S4 cluster. Science (1997) 2.17
The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity (1995) 2.12
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest (1995) 1.70
Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature (1992) 1.60
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet (2009) 1.59
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
Characterization and function of T cell Fc gamma receptor. Immunol Rev (1981) 1.50
Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 1.48
T-cell hybrids bear Fcgamma receptors and secrete suppressor immunoglobulin binding factor. Nature (1979) 1.47
Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc Natl Acad Sci U S A (1999) 1.40
Suppression of in vitro antibody synthesis by immunoglobulin-binding factor. J Exp Med (1975) 1.37
Highly resolved chemical imaging of living cells by using synchrotron infrared microspectrometry. Proc Natl Acad Sci U S A (1998) 1.36
Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity (2001) 1.32
Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol (1998) 1.28
Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level. J Exp Med (1979) 1.27
Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer (1995) 1.25
Role of B cell receptor Ig alpha and Ig beta subunits in MHC class II-restricted antigen presentation. Immunity (1995) 1.25
Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem (2001) 1.21
Role of associated gamma-chain in tyrosine kinase activation via murine Fc gamma RIII. EMBO J (1992) 1.20
Isotype regulation of antibody production: T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors. Proc Natl Acad Sci U S A (1983) 1.19
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant (2008) 1.17
Suppression of mitogen-induced peripheral B cell differentiation by soluble Fc gamma receptors released from lymphocytes. Eur J Immunol (1980) 1.14
Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol Rev (2001) 1.13
Chemical imaging of nucleic acids, proteins and lipids of a single living cell. Application of synchrotron infrared microspectrometry in cell biology. Cell Mol Biol (Noisy-le-grand) (1998) 1.13
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer (1994) 1.12
Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer (1999) 1.11
Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood (1996) 1.11
Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol (1974) 1.10
T cell hybridomas coexpressing Fc receptors (FcR) for different isotypes. II. IgA-induced formation of suppressive IgA binding factor(s) by a murine T hybridoma bearing Fc gamma R and Fc alpha R. J Immunol (1983) 1.10
The role of the Fc receptor (FcR) of thymus-derived lymphocytes. II. Presence of FcR on suppressor cells and direct involvement in suppression. Eur J Immunol (1977) 1.09
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
Interferon enhances the expression of Fc gamma receptors. J Immunol (1980) 1.08
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol (2000) 1.07
Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw (2000) 1.06
Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. Oncogene (1999) 1.06
Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol (1996) 1.05
Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors. J Immunol (1999) 1.05
Ion channel blockers inhibit B cell activation at a precise stage of the G1 phase of the cell cycle. Possible involvement of K+ channels. J Immunol (1990) 1.05
Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity (1999) 1.03
Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation. J Biol Chem (1999) 1.00
Induction of tumor necrosis factor-alpha production by mast cells via Fc gamma R. Role of the Fc gamma RIII gamma subunit. J Immunol (1992) 0.98
Regulation of ITAM signaling by specific sequences in Ig-beta B cell antigen receptor subunit. J Biol Chem (1996) 0.98
Recombinant interleukin 2-activated natural killer cells regulate IgG2a production. Eur J Immunol (1990) 0.98
Cross-linking of IgG receptors inhibits membrane immunoglobulin-stimulated calcium influx in B lymphocytes. J Cell Biol (1993) 0.98
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol (1996) 0.97
Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc gammaRIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol Lett (1996) 0.97
Different patterns of calcium signaling triggered through two components of the B lymphocyte antigen receptor. J Biol Chem (1994) 0.97
Murine recombinant Fc gamma RIII, but not Fc gamma RII, trigger serotonin release in rat basophilic leukemia cells. J Immunol (1992) 0.97
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol (2000) 0.97
Production of an immunoglobulin-binding factor (IBF) by antigen-stimulated lymph node lymphocytes. J Immunol (1974) 0.97
Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res (1998) 0.96
A tyrosine-based signal present in Ig alpha mediates B cell receptor constitutive internalization. J Immunol (1998) 0.96
Molecular heterogeneity of murine mast cell Fc gamma receptors. J Immunol (1990) 0.96
Human virus-infected target cells lacking HLA antigens resist specific T-lymphocyte cytolysis. Nature (1977) 0.95
Recombinant soluble receptors for the Fc gamma portion inhibit antibody production in vitro. Eur J Immunol (1989) 0.95
A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. Hybridoma (1997) 0.95
Development of a direct in situ RT-PCR method using labeled primers to detect cytokine mRNA inside cells. J Immunol Methods (1999) 0.94
Crystal structure of the extracellular domain of a human Fc gamma RIII. Immunity (2000) 0.94
Affinity of the interaction between Fc gamma receptor type III (Fc gammaRIII) and monomeric human IgG subclasses. Role of Fc gammaRIII glycosylation. Eur J Immunol (1997) 0.94
Structure of the mouse beta Fc gamma receptor II gene. J Immunol (1991) 0.94
Mannose receptor ligand-positive cells express the metalloprotease decysin in the B cell follicle. J Immunol (2001) 0.92
Soluble Fc gamma receptors II (Fc gamma RII) are generated by cleavage of membrane Fc gamma RII. Eur J Immunol (1991) 0.92
Distinct intracytoplasmic sequences are required for endocytosis and phagocytosis via murine Fc gamma RII in mast cells. Int Immunol (1993) 0.92
Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB1. J Immunol (1996) 0.92
Defective Fc gamma RII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum. J Immunol (1996) 0.92
[In situ PCR]. Ann Pathol (2000) 0.92
Cytokines and cancer. Int Rev Immunol (1998) 0.92
Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunol Lett (1999) 0.91
Tyrosine-containing activation motif-dependent phagocytosis in mast cells. J Immunol (1994) 0.90
Structural basis of the interaction between IgG and Fcgamma receptors. J Mol Biol (2000) 0.90
Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients. Eur J Cancer Clin Oncol (1982) 0.90
Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors. Eur J Cancer Clin Oncol (1982) 0.90
Negative regulation of hematopoietic cell activation and proliferation by Fc gamma RIIB. Curr Top Microbiol Immunol (1999) 0.89
Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J Immunol (1995) 0.89
Regulatory effects of IgG-BF on hybridoma B cells. molecular characterization of variant cell lines. Mol Immunol (1988) 0.89
Inhibition of the in vitro 19S and 7S antibody response by immunoglobulin-binding factor (IBF) from alloantigen-activated T cells. Cell Immunol (1976) 0.89
Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res (1994) 0.88
Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur J Immunol (1998) 0.88
IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett (1997) 0.87
Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol (1998) 0.87
Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB. J Biol Chem (2000) 0.87
Insufficient phosphorylation prevents fc gamma RIIB from recruiting the SH2 domain-containing protein-tyrosine phosphatase SHP-1. J Biol Chem (2000) 0.86
2.4G2, a monoclonal antibody to macrophage Fc gamma receptors, reacts with murine T cell Fc gamma receptors and IgG-binding factors. Eur J Immunol (1986) 0.86
Effect of virus-induced interferon on the antibody response of suckling and adult mice. Eur J Immunol (1980) 0.86
Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol (2001) 0.86
Fc gamma RII expression in resting and activated B lymphocytes. Eur J Immunol (1989) 0.86
Size and charge heterogeneity of murine IgG-binding factors (IgG-BF). J Immunol (1986) 0.85